Rheumatology 2000; 39: 962-968
© 2000 British Society for Rheumatology
Significance of anticardiolipin and anti-ß2-glycoprotein I antibodies in lupus nephritis
Rheumatology Section, Division of Medicine, Imperial College School of Medicine, Hammersmith Hospital, London W12 ONN, UK
Objective. To investigate whether anticardiolipin (aCL) and anti-ß2-glycoprotein I (anti-ß2GPI) antibodies are associated with lupus nephritis (group II patients), and whether there are differences in the prevalence of these two autoantibodies between group II patients and patients with non-nephritis SLE (group I) and primary antiphospholipid syndrome (PAPS) patients (group III).
Methods. IgG and IgM aCL were measured in 31 patients and anti-ß2GPI in 30 patients with systemic lupus erythematosus (SLE) nephritis and 25 without SLE nephritis and in 36 PAPS patients by validated enzyme immunoassays. Relationships of anti-double-stranded DNA (anti-dsDNA) antibodies and antibodies to the collagenous region of C1q (anti-C1q) with SLE nephritis were also examined.
Results. The prevalence and levels were higher for aCL, but not for anti-ß2GPI, antibodies in group II than in group I patients. Absolute values of aCL and anti-ß2GPI in all three patient groups correlated with each other. The prevalences of aCL, anti-dsDNA and anti-C1q antibodies were significantly higher in group II than in group I and group III patients.
Conclusion. The observations in this paper suggest that raised levels of aCL antibodies are associated with lupus nephritis. We were not able to demonstrate an association between anti-ß2GPI antibodies and kidney disease either in patients with lupus or in patients with primary antiphospholipid syndrome. In SLE, we demonstrated that the presence of anticardiolipin antibodies in conjunction with elevated levels of anti-dsDNA and anti-C1q antibodies is highly specific for glomerulonephritis in patients with lupus.
KEY WORDS: Lupus nephritis, Anticardiolipin, Anti-ß2-glycoprotein I.
Correspondence to: K. A. Davies, Rheumatology Section, Division of Medicine, Imperial College School of Medicine, Hammersmith Campus, Du Cane Road, London W12 ONN, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Hong, T. Wang, C. Huang, W. Cheng, and B. Lin Soy isoflavones supplementation alleviates disease severity in autoimmune-prone MRL-lpr/lpr mice Lupus, September 1, 2008; 17(9): 814 - 821. [Abstract] [PDF]
|
|
|
|
|
|
F. Burling, J. Ng, H. Thein, J. Ly, M.R. Marshall, and P. Gow Ethnic, clinical and immunological factors in systemic lupus erythematosus and the development of lupus nephritis: results from a multi-ethnic New Zealand cohort Lupus, October 1, 2007; 16(10): 830 - 837. [Abstract] [PDF]
|
|
|
|
|
|
M-C Amigo Coagulopathies and the kidney Lupus, October 1, 2004; 13(10): 765 - 768. [PDF]
|
|
|
|
|
|
M H Houman, M Smiti-Khanfir, I B. Ghorbell, and M Miled Systemic lupus erythematosus in Tunisia: demographic and clinical analysis of 100 patients Lupus, March 1, 2004; 13(3): 204 - 211. [Abstract] [PDF]
|
|
|
|
 |
|
 P Alba, L Bento, M J Cuadrado, Y Karim, M F Tungekar, I Abbs, M A Khamashta, D D'Cruz, and G R V Hughes Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis Ann Rheum Dis, June 1, 2003; 62(6): 556 - 560. [Abstract] [Full Text] [PDF]
|
|